BioSpace News Archive

Ocular Therapeutix, Inc. announced interim 7-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration and other retinal diseases.

BD, a leading global medical technology company, launched BD® Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher quality experiments with faster time to insight for scientists working across a range of disciplines including immunology, virology, oncology and infectious disease monitoring.

Eagle Pharmaceuticals, Inc. and Enalare Therapeutics Inc. announced that Enalare has secured a contract for up to $50.3 million from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services.

Cardinal Health plans to release first-quarter financial results for its fiscal year 2023 on November 4, prior to the opening of trading on the New York Stock Exchange.

NMD Pharma A/S announces that the U.S. Food and Drug Administration has granted orphan-drug designation for NMD670, its lead product candidate in development for treatment of myasthenia gravis.

BioRestorative Therapies, Inc. announced that CEO Lance Alstodt will be participating in the Roth Inaugural Healthcare Opportunities Conference being held at The Yale Club in New York City on October 6, 2022.

Aquestive Therapeutics, Inc. announced positive topline results from the EPIPHAST II trial for its AQST-109 epinephrine sublingual film.

Voyager Therapeutics, Inc., a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus capsids, announced that management will participate in the following investor conferences.

Curative Biotechnology Inc. announced that it intends to offer shares of its common stock for sale in an underwritten public offering, after giving effect to the Company’s proposed 1-for-400 reverse stock split.

REGENXBIO Inc. announced that it will present in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on Tuesday, October 4th, 2022.